-
UPDATE on LUPUZOR™ – POSITIVE PROGRESS to PHASE 3 with AVION
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to confirm that final preparations are now underway to progress Lupuzor™ into its new optimised international Phase 3 trial of Lupuzor™ in lupus patients. Further to the recent positive results from the Lupuzor™/P140 Pharmacokinetic (“PK”) study announced on 13 April 2022, we are…
-
UPDATE on P140 (LUPUZOR™) clinical progress. Data confirms positive readout from P140 PK study.
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to provide positive data from the Lupuzor™/P140 pharmacokinetic (“PK”) study, required by the US Food & Drug Administration (”FDA”), as part of the new optimised international Phase 3 trial of Lupuzor™ in lupus patients. Key highlights Data successfully demonstrates the PK study has…
-
LUPUZOR™ UPDATE. PK study commencement approved by MHRA – patient dosing to commence imminently
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to provide an update on the Lupuzor™ pharmacokinetic (“PK”) study, as part of the new optimised international Phase 3 trial of Lupuzor™ in Lupus patients. Key highlights Medical and Health Products Regulatory Agency (“MHRA”) approves commencement of the PK study Volunteers have been…
-
TR1 – Avion Pharmaceuticals – Major Holdings in Shares (10 January 2022)
TR-1: Standard form for notification of major holdings To view notification click here
-
TR1 – Luca Associates – Major Holdings in Shares (4 January 2022)
TR-1: Standard form for notification of major holdings To view notification click here
-
TR1 – Lanstead – Major Holding in Shares
TR-1: Standard form for notification of major holdings To view notification click here
-
Subscriptions and Placing to raise £3.55 million; Sharing Agreement; to fund Investment in R&D pipeline • Company’s Partner Alora and two longstanding investors including Lanstead to participate at an Issue price of 11p – 80% premium to current share price
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce subscriptions and a placing to raise £3.55 million (the “Subscription(s)” and “Placing”) through the issue of 32,272,727 new ordinary shares of 10 pence each in the Company (“Ordinary Shares”) at a price of 11 pence per Ordinary Share (“Issue…
-
Collaboration with Imperial College London
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is very pleased to announce that it has signed a 2-year collaboration agreement with Imperial College London. Under the collaboration, Imperial College will provide significant intellectual input and guidance on a number of innovative peptide assets being developed at our R&D subsidiary, ImmuPharma Biotech in Bordeaux.…
-
CORPORATE UPDATE – The Evolution of ImmuPharma
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to present a comprehensive and detailed update of the significant positive progress achieved since major changes in the Board and Senior Management re-structuring in August 2021. Key highlights Lupuzor™ PK study on track to deliver results in Q1 2022 and to move into…
-
EURONEXT DELISTING – Date: 18 October 2021
ImmuPharma PLC (LSE:IMM; Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, provides an update on its delisting from the Euronext Growth Brussels market, where it has a dual listing with AIM. This proposed de-listing from Euronext Growth Brussels was recently confirmed in the Company’s ‘Corporate Update’ announcement on 29 September 2021. The…
